回盛生物(300871.SZ):上半年化藥製劑實現銷售收入4.21億元,同比增長54.23%
格隆匯8月6日丨回盛生物(300871.SZ)在投資者關係中表示,今年上半年,下游養殖行業景氣度整體較好,公司化藥製劑和原料藥業務持續發力,保持良好的發展態勢。2025年上半年,化藥製劑實現銷售收入4.21億元,較上年同期增長54.23%;獸用原料藥實現銷售收入3.33億元,較上年同期增長199.01%。因公司可轉債贖回,本報吿期可轉債利息計入財務費用同比減少1,130.71萬元,對淨利潤產生一定影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.